NCT01720290View on ClinicalTrials.gov

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 25, 2002

Primary Completion Date

February 25, 2003

Study Completion Date

February 25, 2003

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

Dose individually adjusted

DRUG

metformin

Dose individually adjusted

DRUG

metformin

Dose at 1000 mg/day

Trial Locations (3)

100029

Novo Nordisk Investigational Site, Beijing

100191

Novo Nordisk Investigational Site, Beijing

Unknown

Novo Nordisk Investigational Site, Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY